These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 23336248)

  • 1. Opicapone: a short lived and very long acting novel catechol-O-methyltransferase inhibitor following multiple dose administration in healthy subjects.
    Rocha JF; Almeida L; Falcão A; Palma PN; Loureiro AI; Pinto R; Bonifácio MJ; Wright LC; Nunes T; Soares-da-Silva P
    Br J Clin Pharmacol; 2013 Nov; 76(5):763-75. PubMed ID: 23336248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics, pharmacodynamics and tolerability of opicapone, a novel catechol-O-methyltransferase inhibitor, in healthy subjects: prediction of slow enzyme-inhibitor complex dissociation of a short-living and very long-acting inhibitor.
    Almeida L; Rocha JF; Falcão A; Palma PN; Loureiro AI; Pinto R; Bonifácio MJ; Wright LC; Nunes T; Soares-da-Silva P
    Clin Pharmacokinet; 2013 Feb; 52(2):139-51. PubMed ID: 23248072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations.
    Rocha JF; Falcão A; Santos A; Pinto R; Lopes N; Nunes T; Wright LC; Vaz-da-Silva M; Soares-da-Silva P
    Eur J Clin Pharmacol; 2014 Sep; 70(9):1059-71. PubMed ID: 24925090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of moderate liver impairment on the pharmacokinetics of opicapone.
    Rocha JF; Santos A; Falcão A; Lopes N; Nunes T; Pinto R; Soares-da-Silva P
    Eur J Clin Pharmacol; 2014 Mar; 70(3):279-86. PubMed ID: 24271646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A single- and multiple-dose study to investigate the pharmacokinetics and pharmacodynamics of opicapone, a novel COMT inhibitor, in rat.
    Gonçalves D; Alves G; Fortuna A; Bonifácio MJ; Soares-da-Silva P; Falcão A
    Neuropharmacology; 2017 Oct; 125():146-155. PubMed ID: 28734868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of 3 Single-Dose Regimens of Opicapone on Levodopa Pharmacokinetics, Catechol-O-Methyltransferase Activity and Motor Response in Patients With Parkinson Disease.
    Rocha JF; Ferreira JJ; Falcão A; Santos A; Pinto R; Nunes T; Almeida L; Soares-da-Silva P
    Clin Pharmacol Drug Dev; 2016 May; 5(3):232-40. PubMed ID: 27163503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson's disease.
    Ferreira JJ; Rocha JF; Falcão A; Santos A; Pinto R; Nunes T; Soares-da-Silva P
    Eur J Neurol; 2015 May; 22(5):815-25, e56. PubMed ID: 25649051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of catechol-O-methyltransferase in the cynomolgus monkey by opicapone after acute and repeated administration.
    Kitajima T; Mizote S; Bonifácio MJ; Umemura T; Yoneda K; Moser P; Soares-da-Silva P; Tanaka M
    Neuropharmacology; 2018 Dec; 143():282-288. PubMed ID: 30290160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Opicapone Tablets on Levodopa and 3-O-Methyldopa Pharmacokinetics in Healthy Japanese Subjects: Phase 1 Study.
    Nomoto M; Takeda A; Iwai K; Nishimura A; Hattori N
    Clin Pharmacol Drug Dev; 2021 Feb; 10(2):180-189. PubMed ID: 32416054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opicapone pharmacokinetics and pharmacodynamics comparison between healthy Japanese and matched white subjects.
    Falcão A; Rocha JF; Santos A; Nunes T; Soares-da-Silva P
    Clin Pharmacol Drug Dev; 2016 Mar; 5(2):150-61. PubMed ID: 27138028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of opicapone multiple-dose regimens on levodopa pharmacokinetics.
    Rocha JF; Sicard É; Fauchoux N; Falcão A; Santos A; Loureiro AI; Pinto R; Bonifácio MJ; Nunes T; Almeida L; Soares-da-Silva P
    Br J Clin Pharmacol; 2017 Mar; 83(3):540-553. PubMed ID: 27763682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: a single-center, Phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects.
    Nunes T; Machado R; Rocha JF; Fernandes-Lopes C; Costa R; Torrão L; Loureiro AI; Falcão A; Vaz-da-Silva M; Wright L; Almeida L; Soares-da-Silva P
    Clin Ther; 2009 Oct; 31(10):2258-71. PubMed ID: 19922897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opicapone Pharmacokinetics and Effects on Catechol- O -Methyltransferase Activity and Levodopa Pharmacokinetics in Patients With Parkinson Disease Receiving Carbidopa/Levodopa.
    LeWitt P; Liang GS; Olanow CW; Kieburtz KD; Jimenez R; Olson K; Klepitskaya O; Loewen G
    Clin Neuropharmacol; 2023 Mar-Apr 01; 46(2):43-50. PubMed ID: 36688497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brain and peripheral pharmacokinetics of levodopa in the cynomolgus monkey following administration of opicapone, a third generation nitrocatechol COMT inhibitor.
    Bonifácio MJ; Sutcliffe JS; Torrão L; Wright LC; Soares-da-Silva P
    Neuropharmacology; 2014 Feb; 77():334-41. PubMed ID: 24148813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of opicapone, a third-generation COMT inhibitor, after single and multiple oral administration: A comparative study in the rat.
    Gonçalves D; Alves G; Fortuna A; Soares-da-Silva P; Falcão A
    Toxicol Appl Pharmacol; 2017 May; 323():9-15. PubMed ID: 28322896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic drug evaluation of opicapone for the treatment of Parkinson's disease.
    Svetel M; Tomić A; Kresojević N; Kostić V
    Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):353-360. PubMed ID: 29345156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial.
    Ferreira JJ; Lees A; Rocha JF; Poewe W; Rascol O; Soares-da-Silva P;
    Lancet Neurol; 2016 Feb; 15(2):154-165. PubMed ID: 26725544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological profile of opicapone, a third-generation nitrocatechol catechol-O-methyl transferase inhibitor, in the rat.
    Bonifácio MJ; Torrão L; Loureiro AI; Palma PN; Wright LC; Soares-da-Silva P
    Br J Pharmacol; 2015 Apr; 172(7):1739-52. PubMed ID: 25409768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic Comparison of Capsule and Tablet Formulations of Opicapone in Healthy Japanese Subjects: Phase 1 Study.
    Nomoto M; Takeda A; Iwai K; Nishimura A; Hattori N
    Clin Pharmacol Drug Dev; 2021 Feb; 10(2):173-179. PubMed ID: 32459885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The launch of opicapone for Parkinson's disease: negatives versus positives.
    Castro Caldas A; Teodoro T; Ferreira JJ
    Expert Opin Drug Saf; 2018 Mar; 17(3):331-337. PubMed ID: 29415596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.